Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding increases in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of £10.96 per Ordinary share.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details an increase in share ownership for specific individuals following the re-investment of the dividend paid on July 9, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- The transaction price for the share re-investment was £10.96 per Ordinary share.
- The dividend re-investment occurred on July 9, 2009.
- Directors and managers notified include Mr. A P Witty, Mrs. C M Witty, Mr. J S Heslop, Mr. D Learmouth, Dr. D Pulman, and Mrs. C R Pulman.
- Specific share quantities acquired were: Mrs. C M Witty (429), Mr. J S Heslop (225), Dr. D Pulman (195), Mr. D Learmouth (185), Mr. A P Witty (32), and Mrs. C R Pulman (65).